Innate Pharma (IPHA) Profit After Tax (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Profit After Tax data on file, last reported at -$57.2 million in Q4 2025.

• For the quarter ending Q4 2025, Profit After Tax fell 8.28% year-over-year to -$57.2 million; the trailing twelve-month figure through Dec 2025 stood at -$160.9 million (down 84.86% YoY), and the FY2025 full-year result was -$57.2 million, down 8.28% from the prior year.
• Profit After Tax for Q4 2025 stood at -$57.2 million, down from -$24.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at $618509.1 in Q2 2023 and bottomed at -$60.4 million in Q4 2021.
• The 5-year median for Profit After Tax is -$26.7 million (2024), against an average of -$28.6 million.
• The widest annual swing landed in 2022, when Profit After Tax soared 99.9%; it then tumbled 13639.78% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$60.4 million in 2021, then jumped by 99.9% to -$59279.4 in 2022, then sank by 13639.78% to -$8.1 million in 2023, then slumped by 549.05% to -$52.9 million in 2024, then slipped by 8.28% to -$57.2 million in 2025.
• The last three Profit After Tax figures came in at -$57.2 million (Q4 2025), -$24.2 million (Q2 2025), and -$52.9 million (Q4 2024), per Business Quant data.

Peer Comparison